Variations in serum alkaline DNase activity. A new means for therapeutic monitoring of malignant lymphomas.

Our previously published clinical results suggest that the variations in serum alkaline DNase activity (SADA) could be a reliable marker for the therapeutic monitoring of different human malignancies. The aim of the study documented in this was to determine SADA variations in 27 patients suffering from malignant lymphomas (Hodgkin's and non-Hodgkin's). Patients continued to be observed after therapy. The blood samples were collected before treatment (Time 0), during several days from the onset of each treatment (Phase I), and weeks after the last therapy (Phase II). A decrease in the serum alkaline DNase activity during the first treatment indicates a good clinical response; no decrease indicates a nonresponse to treatment (Phase I). The Phase II data can be used to predict the long-term evolution of the disease. In patients who respond to therapy three types of variations of SADA are observed during this phase. A progressive regain of SADA up to a value exceeding the level of initial value (T0) correlates with a complete remission. An incomplete regain of activity corresponds to a partial remission. No regain of SADA precedes death.